Valneva Reports High Sustained Immune Response in Adolescents One Year After Single Vaccination with its Chikungunya Vaccine
Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported further positive Phase 3 data in adolescents for its single-shot chikungunya virus (CHIKV) vaccine, IXCHIQ®, ...
Hosted on MSN1h
The 11 Deadliest Diseases to Watch for in 2025, According to Experts
If there is one thing that COVID made us aware of, it is the devastating impact that diseases and viruses can have on our ...